Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

NYU Langone's Perlmutter Cancer Center Buzzing With Breast Cancer Research

September 23rd 2019

Thought leaders from NYU Langone’s Perlmutter Cancer Center highlight the latest groundbreaking breast cancer research being conducted at their institution.

Small Subgroups May Hold Big Clinical Clues in Oncology

September 23rd 2019

With the revolution in our understanding of cancer’s basic molecular biology, it is increasingly evident that subgroups of cancer originating from specific regions of the body have unique natural histories and respond to very different therapeutics. For example, the importance of BRCA mutations, which define a subset of ovarian cancers impressively sensitive to PARP inhibitors, has striking altered the management of this group of gynecologic malignancies.

Dr. Westbrook on 3-Year Follow-Up Data of the KRISTINE Trial in HER2+ Breast Cancer

September 20th 2019

Kelly E. Westbrook, MD, discusses the 3-year follow-up data on the KRISTINE trial in stage II or III HER2-positive breast cancer.

Emerging TNBC Agents Show Improved Patient Outcomes

September 19th 2019

Sylvia Adams, MD, discusses the biology of triple-negative breast cancer, data sparking excitement in the field, and intriguing trials on the horizon.

Tumor Biology Drives Personalized Surgical Interventions in Breast Cancer

September 17th 2019

Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.

FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer

September 13th 2019

The FDA is updating the prescribing information and Patient Package Insert for CDK4/6 inhibitors to include a warning that the treatments in rare cases may cause severe inflammation of the lungs.

Novel Therapies Propelling Progress in Breast Cancer

September 12th 2019

Alexander A. Hindenburg, MD, discusses novel agents and ongoing clinical trials supporting their future application in metastatic, hormone receptor–positive, HER2-negative breast cancer.

Expert Anticipates Expansion of Targeted Therapies Aimed at Resistance in Breast Cancer

September 11th 2019

New strategies to address resistance in patients with estrogen receptor–positive breast cancer are in the works, thanks to a greater understanding of the cell-signaling networks activated during the course of disease.

Balancing Genomic and Clinical Risk in HR+ Breast Cancer

September 10th 2019

Nina D’Abreo, MD, explains how treatment is being tailored to women with early-stage, HR-positive, HER2-negative breast cancer.

Dr. Marks on PHENIX Trial Data in HER2+ Breast Cancer

September 10th 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

USPSTF Releases Final Recommendation on Treatments for Reducing Breast Cancer Risk

September 5th 2019

Risk-reducing therapies, such as tamoxifen, raloxifene, or aromatase inhibitors, should be administered to women who are at an increased risk for breast cancer and at a low risk for adverse events associated with these medications.

FDA Grants Neratinib Orphan Drug Status for Breast Cancer With Brain Metastases

September 4th 2019

The FDA has granted an orphan drug designation to neratinib (Nerlynx) for the treatment of patients with breast cancer who have brain metastases.

Dr. Hurwitz on Patient Cohorts in the PIVOT-02 Trial

August 30th 2019

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.

Atezolizumab Plus Nab-Paclitaxel Approved in Europe for Frontline TNBC

August 29th 2019

The European Commission has approved the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, according to Roche (Genentech), the manufacturer of the PD-L1 inhibitor.

FDA Wants Male Patients Factored Into Breast Cancer Drug Development

August 27th 2019

The FDA is hoping to improve the armamentarium for male patients with breast cancer through the issuance of industry guidelines aimed at encouraging the inclusion of male patients in breast cancer clinical trials.

CDK 4/6 Inhibitor Combos Could Have Lasting Benefits in ER+ Metastatic Breast Cancer

August 27th 2019

Although CDK4/6 inhibitors are remaking the treatment landscape for patients with estrogen receptor–positive metastatic breast cancer, questions about optimal sequencing and strategies for attacking resistance and progression remain unsettled.

Fitness Assessments Should Be Integrated Into Care for Older Patients With Breast Cancer

August 27th 2019

Treatment decisions for older patients with breast cancer should be individualized based on the fitness and frailty of the patient, making the use of geriatric assessment tools an essential element of care, according to Armin Shahrokni, MD, MPH.

New Strategies Are Evolving for Breast Cancer Brain Metastases

August 27th 2019

A greater focus on studying mechanisms for therapies that penetrate the blood–tumor barrier and the expansion of clinical trial eligibility criteria are opening the door for advancements that may help patients with metastatic breast cancer that has spread to the brain, according to Carey K. Anders, MD.

First Multilingual App for Breast Exam Aims to Improve Early Cancer Detection

August 25th 2019

Pink Luminous Advocacy Project's Breast Awareness app is the first multilingual, unisex breast self-examination application.

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer

August 23rd 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.